Introduction
Roux-en-y gastric bypass is a successful weight loss surgery together with a great impact on metabolic syndrome. Laparoscopic minigastric bypass is a new emerging bariatric surgery procedure with current debates on its efficacy and safety.
Objectives
The aim of this study was to evaluate the effect of laparoscopic minigastric bypass on weight loss, safety, and associated metabolic diseases.
Patients and methods
The study was performed in Menoufia University Hospital and other private hospitals in Kuwait. All patients underwent laparoscopic minigastric bypass and were followed up for 18 months. Its impact on BMI, %excess weight loss (%EWL), and associated metabolic diseases were reported and analyzed at 6, 12, and 18 months.
Results
A total of 80 patients were included in this study, of whom 49 were female. A total of 58 patients were diabetic, 62 patients were hypertensive, and 69 patients were dyslipidemic. The mean operative time was 92 ± 11.73 min. The mean %EWL was 77.3 ± 9.8%. The mean hospital length of stay was 3 days. One patient had anastomotic leak and two patients had biliary gastritis and were managed with Roux-en-Y gastric bypass. One patient showed marginal ulcer. A total of 47 patients with type 2 diabetes returned to normal glucose level. A total of 51 hypertensive patients became normotensives. A total of 59 patients showed complete improvement in lipid profile after 18 months.
Conclusion
Minigastric bypass is provisionally effective as other standard bariatric surgery procedures, with good impact on associated metabolic diseases.